Production & Manufacturing
BioPharma
CRISPR and Gene Editing: Next-Gen Manufacturing Impacts
The pharmaceutical and biotechnology industries are experiencing a profound technological revolution driven by CRISPR-Cas9 and emerging gene editing technologies that fundamentally alter how therapeutic agents are developed and manufactured. Gene editing pharma manufacturing represents far more than incremental improvement...
BioPharma
Precision Medicine Manufacturing: From Large-Scale to Patient-Centric Production
The pharmaceutical industry is experiencing a fundamental shift away from the traditional โblockbuster drugโ model toward increasingly sophisticated precision medicine manufacturing strategies that prioritize individual patient needs over mass-market volume. This transformation represents far more than a simple adjustment...
BioPharma
AI-Enabled Supply Chain Resilience in Pharmaceutical Manufacturing
Pharmaceutical supply chains are fundamentally evolving as global disruptions, regulatory demands, and patient expectations converge to redefine how drugs reach the market. In todayโs environment, pharmaceutical supply chain resilience depends not only on physical infrastructure and traditional logistics but...
News
Eli Lilly Commits $1.2bn to Modernize Puerto Rico Manufacturing
Governor Jenniffer A. Gonzรกlez Colรณn, along with Sebastiรกn Negrรณn Reichard, the Economic Development and Commerce Secretary, has announced that Eli Lilly and Company, also known as Lilly, is going to invest over $1.2bn to modernize Puerto Rico operations. This...
BioPharma
CDMOs Must Reorganize to Maximize Revenue and Competitiveness
Pharmaceutical businesses increasingly outsource their product development and manufacture to Contract Development and manufacture Organizations (CDMOs), which operate in a fragmented sector that is experiencing significant restructuring. However, a lot of CDMOs put their competitiveness at risk by not...
BioPharma
Investments in the U.S. of Over $70bn Announced by Merck
It is well to be noted that in 2025, a minimum of 14 major pharmaceutical companies across the world went ahead and announced plans to broaden their manufacturing presence in the U.S. so as to lessen the supply chain...
News
LTS Grows U.S. Footprint by Buying CDMO Renaissance Lakewood
As the U.S. production investments continue to roll in 2025, LTS Lohmann, the German pharmaceutical technology specialist, is joining the table with a deal to boost its CDMO firepower in the U.S.
Like many other contract manufacturing expansions that have...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















